Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Pliant Therapeutics, Inc. (PLRX) had Stock-Based Compensation of $4.25M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-20.04M |
|
-- |
|
-- |
|
$21.77M |
|
$-21.77M |
|
$1.73M |
|
$-20.04M |
|
$-20.04M |
|
$-20.04M |
|
$-20.04M |
|
$-20.04M |
|
$-20.04M |
|
$-21.77M |
|
$-21.09M |
|
61.80M |
|
61.80M |
|
$-0.32 |
|
$-0.32 |
|
| Balance Sheet Financials | |
$174.93M |
|
$2.66M |
|
$27.67M |
|
$202.60M |
|
$10.36M |
|
-- |
|
$27.07M |
|
$37.43M |
|
$165.17M |
|
$165.17M |
|
$165.17M |
|
61.91M |
|
| Cash Flow Statement Financials | |
$-19.23M |
|
$-4.10M |
|
$0.07M |
|
$46.93M |
|
$23.67M |
|
$-23.25M |
|
|
Stock-Based Compensation |
$4.25M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.89 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.13M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.13% |
|
-12.13% |
|
-9.89% |
|
-12.13% |
|
$2.67 |
|
$-0.31 |
|
$-0.31 |
|